Targeting the epigenome in ovarian cancer.


Journal Article (Review)

Epithelial ovarian cancer is the leading cause of death from gynecological cancers, largely owing to the development of recurrent intractable disease. Only a small number of distinct genetic mutations are known to contribute to ovarian carcinogenesis. Furthermore, understanding mechanistic genotype-phenotype links is complicated by frequent aneuploidy. Epigenetic deregulation is even more prominent, and ovarian cancers are replete with such aberrations that repress tumor suppressors and activate proto-oncogenes. Epigenetic therapies are emerging as promising agents for resensitizing platinum-resistant ovarian cancers. These drugs may also have the potential to alter epigenetic programming in cancer progenitor cells and provide a strategy for improving therapy of ovarian cancer.

Full Text

Duke Authors

Cited Authors

  • Murphy, SK

Published Date

  • February 2012

Published In

Volume / Issue

  • 8 / 2

Start / End Page

  • 151 - 164

PubMed ID

  • 22335580

Pubmed Central ID

  • 22335580

Electronic International Standard Serial Number (EISSN)

  • 1744-8301

Digital Object Identifier (DOI)

  • 10.2217/fon.11.152


  • eng

Conference Location

  • England